Relation of change in apolipoprotein B/apolipoprotein A-I ratio to coronary plaque regression after Pravastatin treatment in patients with coronary artery disease

The American Journal of Cardiology
Shigemasa TaniAtsushi Hirayama

Abstract

Some investigations have looked into the ability of measurements of apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio to predict cardiovascular events. We hypothesized that a decrease in the apoB/apoA-1 ratio by statin therapy would act on suppression of coronary plaque progression. A 6-month prospective study was conducted of 64 patients with coronary artery disease treated with pravastatin. The plaque volume, assessed by volumetric intravascular ultrasonography, had decreased significantly by 12.6% (p <0.0001 vs baseline). Although a significant decrease of 6.4% and 14.6% was found in the serum level of apoB and the apoB/apoA-1 ratio (p = 0.0001 and p <0.0001, respectively, vs baseline), a significant increase of 14.0% of and 12.0% in the level of apoA-I and apoA-II (both p <0.0001 vs baseline). No significant changes were found in the level of apoC-II or apoE. A stepwise regression analysis revealed that the change in the apoB/apoA-1 ratio was an independent predictor of the change in coronary plaque volume (beta coefficient 0.386; p = 0.0023). In conclusion, our results have indicated that the decrease in the apoB/apoA-I ratio is a simple predictor for coronary atherosclerotic regression: the lower the apoB/apoA-I rat...Continue Reading

References

Oct 15, 2003·The American Journal of Cardiology·Kazutoshi IshikawaKatsuo Kanmatsuse
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
Oct 11, 2005·The American Journal of Cardiology·Shigemasa TaniUNKNOWN Surugadai Atherosclerosis Regression Investigators
Mar 15, 2006·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN ASTEROID Investigators
Feb 8, 2007·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
May 31, 2007·Revista española de cardiología·Lars RydénInga Thrainsdottir
Jun 4, 2008·Circulation·John J P KasteleinUNKNOWN IDEAL Study Group
Jul 8, 2008·Journal of Atherosclerosis and Thrombosis·Tamio TeramotoMasayuki Yokode
Aug 8, 2009·The American Journal of Cardiology·Shigemasa TaniAtsushi Hirayama

❮ Previous
Next ❯

Citations

Jun 16, 2010·Cardiovascular Drugs and Therapy·Nesan ShanmugamJuan Carlos Kaski
Oct 11, 2012·Vascular Health and Risk Management·Atul Ashok KalanuriaGeoffrey Ling
Jul 4, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Shigemasa TaniAtsushi Hirayama
May 26, 2020·The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology·Haitham GalalMohamed Shehata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.